Drugs / SCRI-E2CAR_EGFRtv1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05312411 | May 2022 → Mar 2025 overdue | osteosarcoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCRI-E2CAR_EGFRtv1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05312411 ↗ |
| Action | Deplete | “When the CAR T cells see the labeled tumor cells they can kill the tumor cells.” NCT05312411 ↗ |
| Modality | Cell therapy | “Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)” NCT05312411 ↗ |
| Route | Other | “CAR T cell infusion” NCT05312411 ↗ |